Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function in human cancer. Murine Kras-driven lung cancer models have confirmed the key ...

In non-small cell lung cancer (NSCLC), the leading cause of cancer-related death, KRAS mutations are found in 25-30% of all cases with non-squamous histology. The KRAS-G12C mutation, specifically ...

This suggests a model in which lung damage from smoking or ... There are multiple cancer drugs that specifically target mutated KRAS, but these mostly deliver only limited clinical benefit.

Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function in human cancer. Murine Kras-driven lung cancer models have confirmed the key ...

Merck & Co’s Keytruda reigns supreme among immunotherapies for non-small cell lung cancer (NSCLC), and new data looks set to consolidate that position even further with new data in KRAS-positive ...

Next, using two mouse models of KRAS-driven lung cancer, investigators inactivated ... the spatial precision facilitated by ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

the team used a model with tobacco carcinogen exposure, which creates lung damage like that incurred by cigarette smoke. They ...

A new collaborative study from Karolinska Institutet published in Science Advances shows that the levels of mitochondrial DNA ...

The research will test immunotherapies – treatments that harness the power of our immune system – to treat patients with a specific kind of lung cancer (KRAS-mutant), which is particularly ...

Roche also axed a trial for divarasib, specifically a phase 2/3 trial that was comparing the KRAS G12C inhibitor to docetaxel in the second-line treatment of non-small cell lung cancer (NSCLC).